阿库提斯生物制药

最新新闻

• Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36
  \u5e02\u573a\u8d44\u8baf · 2026/7/1
• 评级变动
  A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $37
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• 评级变动
  Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Cuts Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/2/28
• 评级变动
  Goldman Sachs Maintains Arcutis Biotherapeutics(ARQT.US) With Hold Rating, Raises Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 评级变动
  TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/1/29
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)
  TipRanks · 2026/5/26
• 评级变动
  A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $34
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/5/26
• A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $37
  \u5e02\u573a\u8d44\u8baf · 2026/1/27
• 评级变动
  Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/4/22
• 评级变动
  Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• Form 144 | Arcutis Biotherapeutics(ARQT.US) Insider Proposes to Sell 8.55 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• 评级变动
  H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/2/3
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)
  TipRanks · 2026/8/11
• 评级变动
  Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $31
  \u5e02\u573a\u8d44\u8baf · 2026/1/27
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN)
  TipRanks · 2026/4/22
• 评级变动
  TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/4/23

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。